DMDora María Frias Márquez

Dora María Frias Márquez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dora María Frias Márquez has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Photocatalytic Reduction of 4-Nitrophenol over Bismuth Sulfur/Titanium Dioxide Heterojunction: Influence of Bismuth Sulfur Content on the Reaction Efficiency

    by Cinthia García-Mendoza, Mayra Angélica Alvarez-Lemus, Rosendo López-González, Dora María Frias Márquez, Gabriela Jácome-Acatitla

    Photocatalytic reduction of 4-nitrophenol is one of the most promising methods to remove this hazardous pollutant from wastewaters and generated a raw compound widely use in industrial processes. In the present work, three Bi2S3/TiO2 catalysts with different Bi2S3 content, were synthesized by a hydrothermal method. The materials were characterized by XRD, X-ray fluorescence, physisorption of N2, HRTEM, UV-Vis reflectance spectroscopy and zeta potential measurements. The catalytic activity of the synthesized materials was tested in the photoreduction of 4-nitrophenol in aqueous medium. Although the results indicate the formation of heterojunction for all the samples, the physicochemical properties of each material depend on the Bi2S3 content. The material with 6%wt of Bi2S3 exhibit the major catalytic activity, reducing 80% of the target molecule within 60 minutes of reaction.


  • Open Access

    Albendazole Release from Silica-Chitosan Nanospheres. In Vitro Study on Cervix Cancer Cell Lines

    by Daniela J. Hernández-Castillo, Erick Natividad de la Cruz Hernández, Dora M. Frías Márquez, Richard D. Tilley, Lucy Gloag, Patricia Quintana Owen, Rosendo López González, Mayra A. Alvarez Lemus

    In this work, a pH-responsive drug-carrier based on chitosan-silica nanospheres was developed as a carrier for Albendazole (ABZ), a poorly water-soluble anthelmintic drug. Spherical silica nanoparticles were obtained by Stöber method and further etched to obtain mesoporous particles with sizes ranging from 350 to 400 nm. The specific BET area of nanoparticles increased from 15 m2/g to 150 m2/g for etched silica, which also exhibited a uniform pore size distribution. X-ray powder diffraction showed the presence of amorphous phase of silica and a low-intensity peak attributed to ABZ for the drug-loaded nanoparticles. A uniform layer of chitosan was obtained ranging from 10 to 15 nm in thickness due to the small concentration of chitosan used (0.45 mg of chitosan/mg of SiO2). The in vitro evaluation of hybrid nanoparticles was performed using four cervical cancer cell lines CaSki, HeLa, SiHa and C33A, showing a significant reduction in cell proliferation (>85%) after 72 h. Therefore, we confirmed the encapsulation and bioavailability of the drug, which was released in a controlled way, and the presence of chitosan delayed the release, which could be of interest for the development of prolonged release drug delivery systems.